ArticleCancer medicine2023

The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer.

Takayuki Honda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.